CAR-T therapy-associated T-cell malignancies that the US FDA is investigating could make the treatments less attractive in autoimmune diseases than in oncology, but patients in both settings already accept some cancer risk with other available medicines.

Hopes are that the impact of the US FDA’s investigation into a small number of T-cell malignancies associated with CAR-T therapies will be small since the benefit/risk profile still looks sound.

The amendment to a December 2022 deal expands their myeloma CAR-T partnership and will see development of CART-ddBCMA in lymphomas, where research indicates anti-BCMA therapy has activity.

The Swiss drug maker is licensing multiple DLL3-targeting CAR-Ts from the Chinese biotech, including one already in early clinical development, and will use its T-Charge manufacturing platform.